{"id":133,"date":"2013-04-15T12:53:40","date_gmt":"2013-04-15T12:53:40","guid":{"rendered":"http:\/\/www.farmacovigilanciacanarias.org\/noticias\/?p=133"},"modified":"2013-04-15T12:53:40","modified_gmt":"2013-04-15T12:53:40","slug":"nota-informativa-muh-fv-102013","status":"publish","type":"post","link":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/2013\/04\/15\/nota-informativa-muh-fv-102013\/","title":{"rendered":"Nota Informativa MUH (FV), 10\/2013"},"content":{"rendered":"<p><a href=\"http:\/\/www.aemps.gob.es\/informa\/notasInformativas\/medicamentosUsoHumano\/seguridad\/2013\/NI-MUH_FV_10-2013-tetrazepam.htm\">Tetrazepam (Myolastan\u00ae): Actualizaci\u00f3n de la informaci\u00f3n sobre la revisi\u00f3n europea del balance beneficio-riesgo<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Tetrazepam (Myolastan\u00ae): Actualizaci\u00f3n de la informaci\u00f3n sobre la revisi\u00f3n europea del balance beneficio-riesgo<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7,4],"tags":[],"class_list":["post-133","post","type-post","status-publish","format-standard","hentry","category-alertas","category-seguridad"],"_links":{"self":[{"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/posts\/133","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/comments?post=133"}],"version-history":[{"count":1,"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/posts\/133\/revisions"}],"predecessor-version":[{"id":134,"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/posts\/133\/revisions\/134"}],"wp:attachment":[{"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/media?parent=133"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/categories?post=133"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.farmacovigilanciacanarias.org\/noticias\/wp-json\/wp\/v2\/tags?post=133"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}